{‘She has no qualifications’: this US medical field girds for Høeg's appointment at the Food and Drug Administration.

Given that the US undertakes historic changes to its vaccine guidelines, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by expressing skepticism about Covid shots throughout the global health crisis and has focused upon possible deaths following Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Program

Public health authorities planned to reveal major revisions to the pediatric vaccination calendar recently, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would place the US out of alignment with much of the international standard with no evidence for improved outcomes. This reveal has been delayed until the new year.

In place of the director of the vaccine center, Høeg is scheduled to present at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to lead the center this year.

A Shift at the Agency

This interim role could signify a strengthened alliance between the drug and biologics branches as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific pediatric immunization guidelines in the US to become more similar to Denmark, a nation with nationalized medicine and a population approximately the population of the state of Wisconsin.

In her initial comments, she has persisted in emphasizing on immunizations – typically the responsibility of Prasad, chief of the FDA’s CBER – rather than medication approval.

Concerns Over Qualifications

Høeg has little discernible track record in drug development, approval processes or management, which has been typical for former heads of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She appears not to have any of the qualifications” for running the drug-regulation department, said a neurologist and psychiatrist. “She’s never run a scientific study. She lacks experience in running a major agency. She is not an expert in industry regulation.”

Previous directors of the center would “understand regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that former directors who headed CBER have had.”

CDER has an immense portfolio at the agency, she stated.

“Everybody just pays attention on the new drug program, but the generic program clears a multitude of generic medications. There is also a biosimilars program, OTC medication office and more, and all of those must be managed,” Woodcock noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

There is also, a major management component to the job, which manages in excess of 5,000 staff members. “It is a huge leadership role, if you execute it properly,” she added.

Response and Contentious Policies

Regarding inquiries about Høeg’s qualifications and whether this appointment indicates more teamwork among regulatory chiefs on vaccines, a representative stated that the “inquiries rely on incorrect premises”.

“This background is consistent with the duties of her role,” the spokesperson stated, citing the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As acting director, Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious expedited medication authorization process that reportedly worried her predecessors. “By what process are these medications being selected for this fast-track system? Who is making the calls?” Howard asked. “There is a lot of lack of transparency going on at the agency right now.”

Overall, he said, “the agency looks to be trending towards laxer rules of all drugs, aside from shots.”

Established History on Immunizations

With vaccines, Dr. Høeg has a more documented, if problematic, past, critics have noted. She released a study using non-validated crowd-sourced reports to estimate the rate of myocarditis following COVID-19 immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the new federal leadership included revising regulations for new vaccines and halting “non-essential” immunizations, she said post-election on a online show. At the FDA, Dr. Høeg has reportedly suggested excluding teenage boys from obtaining COVID-19 vaccines.

“She is an all-around true believer who begins with her beliefs and tailors the evidence to fit the science in a very deceptive, untruthful manner,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined fellow dissenters, {like|